ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain

NEXT STORY
Point-of-Care Molecular Diagnostics Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Product & Services, Technology [PCR, Isothermal Nucleic Acid Amplification Technology, and Other Technologies], Application, and End User Geography
PREV STORY
Adagio Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

electroCore, Inc. Announces Third Quarter Financial Results

BASKING RIDGE, N.J., Nov. 13, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq: ECOR), ...

author_avatar
NASDAQ Market News

Salarius Announces Publication of Scientific Paper Highlighting Potential of Combining Seclidemstat with Checkpoint Inhibitors

author_avatar
NASDAQ Market News

Generex Biotechnology Announces Date for Rescheduled May 15th Investor Conference Call to Present Organizational Roadmap & Update on Investor Dividend, Product Launch, New Acquisitions, Financing, Expansion Initiatives & Strategic Plans

author_avatar
NASDAQ Market News